This study focuses on evaluating serum parathyroid hormone (PTH), C-reactive protein (CRP), lipid profile parameters, and interleukin-6 (IL-6) in relation to the stages of lung cancer, exploring their potential as biomarkers for assessing disease severity. Here, IL6 is linked to lung carcinoma.